- Home
- CEPF vs AQST Comparison
CEPF vs AQST Comparison
Compare CEPF & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$4.86
Company Overview
Basic Information| Metric | CEPF | AQST |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 529.4M |
| IPO Year | 2025 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CEPF | AQST |
|---|---|---|
| Price | $10.37 | $4.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 48.4K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | $96.45 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $10.13 | $2.94 |
| 52 Week High | $10.67 | $7.55 |
Technical Indicators
Market Signals| Indicator | CEPF | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 50.32 |
| Support Level | $10.31 | $4.03 |
| Resistance Level | $10.48 | $5.10 |
| Average True Range (ATR) | 0.04 | 0.25 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 23.33 | 18.28 |
Price Performance
Historical Comparison CEPF
AQST
About CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares
Cantor Equity Partners IV Inc is a blank check company.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.